Supplement 3. Disclosure of Interest Forms of the Review Team for the ASH 2020 Guidelines for Management of Venous Thromboembolism in Latin America

Izcovich

Karzulovic

Neumann

Rada

Schünemann

Vera

Zhang



Part A. Material Interests in Companies				
 Equity 1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares. ☑ No ☐ Yes, as described below: Add rows as needed for each equity interest. 				
Company	Description	Date Divested	For ASH Internal Use	
Patents and Royalties 2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions? □ No □ Yes, as described below: Add rows as needed for each patent or royalty interest.				

used

Company	Description	Date Divested	For ASH Internal Use

Personal Income or Other Remuneration

3.	remunerat company tl	Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies us to diagnose, treat, monitor, manage, or alleviate health conditions?			
	⊠ No				
	☐ Yes, as o	described below:			
	Column 1	Name the company.			
	Column 2	Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.			

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Сотрапу	Description	End Date	For ASH Internal Use

Industry-Funded Research

4.	Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?		
	⊠ No		
	☐ Yes, as o	described below:	
	Column 1	Name the company funding or supporting the research.	
	Column 2	Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.	
	Column 3	Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.	
	Column 4	Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")	
	Add rows a	is needed for each research project.	

Company	Description of Research	My Role	End Date	For ASH Internal Use

My Partner's or Spouse's Interests

IVI	y Farther's or Spouse's interests
5.	Currently or in the past 24 months has <i>your partner or spouse</i> had any of the interests described in questions 1-4?
	⊠ No
	☐ Yes, as described below:

Add rows as needed for each interest.

Company	Description	End Date	For ASH Internal Use

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

A	SH Guidelines on Venous Thromboembolism for Latin America
or	e questions that follow are designed to elicit information about personal beliefs, intellectual positions opinions, institutional relationships, and other interests that are not mainly financial and that may be evant to guidelines on the above topic(s).
Ре 1.	Personal Beliefs Do you have strongly held beliefs related to the topic of these guidelines?
	⊠ No
	□ Yes
	If yes, please explain:
Pr 2.	reviously Published Opinions Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
	⊠ No
	□ Yes
	If yes, what were those views and where were they made?
Re	esearch
3.	Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
	⊠ No

	☐ Yes, as	described l	below:		
	Column 1	Name the	entity funding the researc	h.	
	Column 2	Describe t	the research project.		
	Column 3	steering c	your role: (a) national or ov ommittee of a study that o or. If other than these opti	loes not have a principal in	
	Column 4		when your involvement end dicate "current" or "ongoir		involvement has not yet
	Add rows	as needed f	for each research project.		
F	under		Description of Research	My Role	End Date
1.		nerate revei , testifying,	nues or nonfinancial benef writing, or otherwise shari		
	⊠ No				
	☐ Yes				
	If yes, plea	se explain:			
5.	Could your	· institution	benefit or be harmed by r	ecommendations of guide	lines on this topic?
	☐ Don't kı	now			
	⊠ No				
	☐ Yes				
	If yes, plea	se explain:			

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Advocacy and Policy Positions

7.	Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?
	⊠ No
	□ Yes
	If yes, are you involved in formulating or voting for positions?
	□ No
	□ Yes
	If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?
	☐ Don't know or not applicable
	□ No
	□ Yes
	If yes, please explain:
Pr	ofessional Specialty
8.	What is your primary clinical specialty or subspecialty? General Internal Medicine
9.	Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
	□ No
	⊠ Yes
	If yes, please explain:

Expected Interests

10.	Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?			
	⊠ No			
	□ Yes			
	If yes, please describe:			

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publicly available.

Name of guideline panel(s)	ASH Guidelines on Venous Thromboembolism for Latin America
----------------------------	--

Reviewer name and date	Direct Financial Conflicts?	Indirect Financial Conflicts?	Management Notes
Alexander, 8/18/17	No	No	Dr. Izcovich has no current direct or indirect conflicts of interest.
Castano, 8/31/2020	No	No	Dr. Izcovich has no current direct or indirect conflicts of interest. On August 31, 2020 Dr. Neumann confirmed all information on this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	Description	Disclosure Date	ASH Notes

Notes:

Dr. Izcovich is a member of the methods team.

Part A. Direct Financial Interests in or Relationships With Companies							
that develops, produc	Employment 1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?						
\square Yes, as described b	elow:						
Add rows as needed for	or each employment relati	onship.					
Сотрапу	Company Description End Date For ASH Internal Use						
Equity							
2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.							
⊠ No							
\square Yes, as described b	☐ Yes, as described below:						
Add rows as needed for	Add rows as needed for each equity interest.						

Company		Description	Date Divested	For ASH Internal Use
Patents, R	oyalties,	, and Other Intelle	ectual Property	
•	ctual prope	•	you owned patents for or rignose, treat, monitor, man	•
⊠ No				
☐ Yes, as (described b	elow:		
			intonost	
Add rows a	is needed to	or each patent or royalty	interest.	
Сотрапу		Description	Date Divested	For ASH Internal Use
4. Do you cur transfers o profit com	rently or in f value (e.g pany that d	., honoraria, gifts, travel s evelops, produces, marke	ensfers of Value you received any personal support, meeting registratio sts, or distributes drugs, dev hage, or alleviate health cor	n, meals) from any for- ices, services, or
 Do you cur transfers o profit com 	rently or in f value (e.g pany that d	the past 24 months have ., honoraria, gifts, travel s evelops, produces, marke	you received any personal upport, meeting registrationts, or distributes drugs, dev	n, meals) from any for- ices, services, or
 Do you cur transfers o profit com therapies u No 	rently or in f value (e.g pany that d	the past 24 months have ., honoraria, gifts, travel s evelops, produces, marke gnose, treat, monitor, ma	you received any personal upport, meeting registrationts, or distributes drugs, dev	n, meals) from any for- ices, services, or
 Do you cur transfers o profit com therapies u No 	rently or in f value (e.g pany that d used to diag	the past 24 months have ., honoraria, gifts, travel s evelops, produces, marke gnose, treat, monitor, ma	you received any personal upport, meeting registrationts, or distributes drugs, dev	n, meals) from any for- ices, services, or

or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	Description	End Date	For ASH Internal Use

My Partner's or Spouse's Interests

5.	5. Currently or in the past 24 months has <i>your partner or spouse</i> had any of the interests or relationships described in questions 1-4?						
	⊠ No						
	☐ Yes, as described below:						
	Add rows as needed for each interest.						
Co	Company Description End Date For ASH Internal Use						

Part B. Indirect Financial Interests in or Relationships With Companies

1. Through your institution, do you currently or in the past 24 months have you been involved in

Industry-Funded Institutional Research

Add rows as needed for each research project.

	research funded or supported (e.g., in kind support, such as provision of a study drug) by any for- profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?							
	⊠ No							
☐ Yes, as described below:								
	Column 1	Name the company funding or supporting the research.						
	Column 2	Briefly describe the research project.						
	Column 3	Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.						
	Column 4	Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")						

Company	Description of Research	My Role	End Date	For ASH Internal Use

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

	markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?						
	⊠ No						
	☐ Yes, as descri	bed be	low:				
	Column 1 Nam	ne the (organization. If known to yo	ou, describe a	ny industry f	funding or support.	
			cribe your activity and role, nteer services.	e.g., employi	ment, servic	e on board of directors,	
	Column 3 India	cate if	your activity was paid or vo	lunteered.			
			nen your involvement with ded, indicate "current" or "		ion ended. (If your involvement has	
	Add rows as nee	ded fo	r each organization.				
0	rganization		Description and role	Paid or Unpaid?	End Date	For ASH Internal Use	
Ot 3.	produces, marke	ets, or o	rect interests in or relation distributes drugs, devices, s leviate health conditions?		•		

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guidelines on Venous Thromboembolism for Latin America

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

rele	evant to guidelines on the above topic(s).
	ersonal Beliefs Do you have strongly held beliefs related to the topic of these guidelines?
	⊠ No
	□ Yes
	If yes, please explain:
	eviously Published Opinions
2.	Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
	⊠ No
	□ Yes
	If yes, what were those views and where were they made?
	on-Industry Supported Research
3.	Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
	⊠ No
	☐ Yes, as described below:

	Column 2	Describe t	the research project.			
	Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or loc investigator. If other than these options, please describe.					
	Column 4		when your involvement end dicate "current" or "ongoir		nvolvement has not yet	
	Add rows	as needed f	or each research project.			
Fı	under		Description of Research	My Role	End Date	
n	stitution	al Dalati	onshins			
1. 1.			ffected by recommendation	ons on this topic?		
	□ Don't kr	now	·	·		
	⊠ No					
	☐ Yes					
	If yes, plea	se explain:				
	, , , , , , ,					
5.			nues for your institution or writing, or otherwise shari			
	☐ Don't kr	now				
	⊠ No					
	□ Yes					
	If yes, plea	se explain:				

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Column 1 Name the entity funding the research.

	☐ Don't know					
	⊠ No					
	□ Yes					
	If yes, pleas	se explain:				
Ca	reer Adv	/anceme	ent			
7.	or other er	ntities if you om peers o	cterize the support you would receive for work on this panel or authorship of toutside your institution? I wouldn`t get provide in the control of the contro	nese guidelines generated a strong		
	Do you wo	rk for or are	ganizations With Relevant F e you a member of an organization with g., position statement, editorial, blog, a	a stated position related to the topic		
	⊠ No					
	☐ Yes, as o	described b	elow:			
	Column 1	Name the	organization.			
	Column 2	Describe of these g		organization that is related to the topic		
	Column 3		your role at the organization, including g, or implementing relevant positions.	your involvement in deciding,		
	Add rows as needed for each organization.					
Or	ganization		Relevant Policy Position	Your Role		

Clinical Practice 9. Do you see patients clinically?

9.	bo you see patients clinically?
	□ No
	⊠ Yes
	If yes, what is your primary specialty or subspecialty? Pediatrics
	If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?
	⊠ No
	□ Yes
	If yes, please explain:
Ex	pected Interests
10.	Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?
	⊠ No
	□ Yes
	If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	Description	Disclosure Date	ASH Internal Notes

Part E. Summary (ASH Internal Use)

Name of guideline panel(s) ASH Guidelines on Venous Thromboembolism for Latin America
--

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	Direct Financial Conflicts?	Indirect Financial Conflicts?	Management Notes
Castano, 10/07/2019	No	No	Dr. Karzulovic does not have any direct or indirect conflicts with companies that can be affected by the guidelines.
Castano, 09/01/2020	No	No	On September 1, 2020 Dr. Karzulovic confirmed all information on this form.

Summary of Direct Financial Conflicts

Company	Description	Disclosure Date	ASH Notes
	[Describe in plain language the personal income or direct transfer of value and the activity for which it was received. If relevant, describe the specific amount.]		[Describe why this direct financial interest or relationship is judged to be a conflict by ASH.]

Other Notes

[Describe other disclosed interests or relationships that may be important to highlight to the guideline panel, guideline reviewers, and guideline users.]



Part A. Material Interests in Companies						
Equity 1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.						
☐ Yes, as described be						
Add rows as needed fo	or each equity interest.					
Company	Description	Date Divested	For ASH Internal Use			
Patents and Royalties 2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions? □ No □ Yes, as described below: Add rows as needed for each patent or royalty interest.						

Company	Description	Date Divested	For ASH Internal Use

Personal Income or Other Remuneration

Э.	remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?				
	⊠ No				
	☐ Yes, as described below:				
	Column 1	Name the company.			
	Column 2	Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.			
	Column 3	Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")			

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

Company	Description	End Date	For ASH Internal Use

Industry-Funded Research

4.	Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?				
	⊠ No				
	☐ Yes, as o	described below:			
	Column 1	Name the company funding or supporting the research.			
	Column 2	Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.			
	Column 3	Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.			
	Column 4	Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")			
	Add rows a	s needed for each research project.			

Company	Description of Research	My Role	End Date	For ASH Internal Use

IVI	y Partner's or Spouse's Interests
5.	Currently or in the past 24 months has <i>your partner or spouse</i> had any of the interests described in questions 1-4?
	⊠ No
	\square Yes, as described below:

Add rows as needed for each interest.

Company	Description	End Date	For ASH Internal Use

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

AS	SH Guidelines on Venous Thromboembolism for Latin America
or o	e questions that follow are designed to elicit information about personal beliefs, intellectual positions opinions, institutional relationships, and other interests that are not mainly financial and that may be evant to guidelines on the above topic(s).
	prsonal Beliefs Do you have strongly held beliefs related to the topic of these guidelines?
	⊠ No
	□ Yes
	If yes, please explain:
Pr 2.	eviously Published Opinions Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
	⊠ No
	□ Yes
	If yes, what were those views and where were they made?
D -	and and b
Ке 3.	esearch Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?
	⊠ No

	☐ Yes, as described below:							
Column 1 Name the entity funding the research.								
	Column 2	Describe the research project.						
	Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or investigator. If other than these options, please describe.							
	Column 4		vhen your involvement end dicate "current" or "ongoil		e. (If your i	nvolvement has not yet		
	Add rows	as needed f	for each research project.					
Fı	under		Description of Research	My Role		End Date		
	Do you ger consulting, topic?	onal Relationships generate revenues or nonfinancial benefits for your institution by teaching, speaking, ng, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline						
	□ Don't kı	now						
	⊠ No							
	☐ Yes If yes, plea	co ovalaja:						
	ii yes, piea	se explain.						
5.	Could your	· institution	benefit or be harmed by r	ecommendatio	ns of guide	lines on this topic?		
	☐ Don't kı	now						
	⊠ No							
	☐ Yes							
	If yes, plea	se explain:						

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Advocacy and Policy Positions

7.	Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?
	⊠ No
	□ Yes
	If yes, are you involved in formulating or voting for positions?
	□ No
	□ Yes
	If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?
	☐ Don't know or not applicable
	□ No
	□ Yes
	If yes, please explain:
Pr	ofessional Specialty
8.	What is your primary clinical specialty or subspecialty? General Internal Medicine
9.	Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
	□ No
	⊠ Yes
	If yes, please explain:

DVT/PEs are diagnosed and treated by internists in my setting.

10.	Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
	⊠ No
	□ Yes
	If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publicly available.

Name of guideline panel(s)	ASH Guidelines on Venous Thromboembolism for Latin America
----------------------------	--

Reviewer name and date	Direct Financial Conflicts?	Indirect Financial Conflicts?	Management Notes
Alexander, 8/18/17	No	No	Dr. Neumann has no current direct or indirect conflicts of interest.
Castano, 8/31/2020	No	No	Dr. Neumann has no current direct or indirect conflicts of interest. On August 31, 2020 Dr. Neumann confirmed all information on this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	Description	Disclosure Date	ASH Notes

Notes:

Dr. Neumann is the lead methodologist and the facilitator for this panel.

Equity 1. Do you currently or in the past 24 months have you had equity in any for-profit compan develops, produces, markets, or distributes drugs, devices, services, or therapies used to	o diagnose,					
1. Do you currently or in the past 24 months have you had equity in any for-profit compan	o diagnose,					
treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock option other ownership interests but excludes diversified mutual fund shares.						
⊠ No						
\square Yes, as described below:						
Add rows as needed for each equity interest.						
Company Description Date Divested For ASH Internal Use						
Patents and Royalties						
2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?						
⊠ No						
☐ Yes, as described below:						
Add rows as needed for each patent or royalty interest.						
Company Description Date Divested For ASH Inte	ernal Use					

Personal Income or Other Remuneration

3.	Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?					
	⊠ No					
	☐ Yes, as o	described b	elow:			
	Column 1	Name the	company.			
	Column 2	employme	he activity for which you rent, consultancy, speakers e or board, expert testimo	bureau involvement, servi		
	Column 3		when the activity ended, if a current" or "ongoing.")	applicable. (If the activity h	nas not yet ended,	
	Add rows a	s needed fo	or each activity.			
	To report a	ctivities tha	at generate revenues for yo	our institution, see Part B,	Question 4.	
Company Description End Date For ASH Internal Use						
n I.	ndustry-Funded Research Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?					
	⊠ No					
	☐ Yes, as o	described b	elow:			
	Column 1	Name the	company funding or supp	orting the research.		
	Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.					

- Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
- Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	Description of Research	My Role	End Date	For ASH Internal Use

My Partner's or Spouse's Interests

IVI	y raither's or spouse's interests
5.	Currently or in the past 24 months has <i>your partner or spouse</i> had any of the interests described in questions 1-4?
	⊠ No
	☐ Yes, as described below:
	Add rows as needed for each interest.

Company	Description	End Date	For ASH Internal Use

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Topic	Guideline Panel	
Venous thromboembolism (VTE)	VTE Guideline Coordination Panel	
Prevention of VTE in medical hospitalized patients	Guideline Panel on Prevention of VTE in	
	Medical Hospitalized Patients	
Prevention and treatment of VTE in patients with	Guideline Panel on Prevention and Treatment	
cancer	of VTE in Patients with Cancer	
Diagnosis of VTE	Guideline Panel on Diagnosis of VTE	

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1.	Do you have strongly held beliefs related to the topic of these guidelines?		
	⊠ No		
	□ Yes		
	If yes, please explain:		
Pr	reviously Published Opinions		
2.	Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?		
	□ No		
	⊠ Yes		
	If yes, what were those views and where were they made?		
-	ACCP AT Guidelines		

- CHEST since edition 6 to 9
- Cochrane reviews on antithrombotic use in patients with cancer
- NEJM editorial on update of a systematic review on antithrombotics with cancer

- JAMA Clinical Synopsis – heparin in cancer patients undergoing surgery

Research

project not	Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g research project funded by a nonprofit or governmental organization?	
□ No		
⊠ Yes, as	described below:	
Column 1	Name the entity funding the research.	
Column 2	Describe the research project.	
Column 3	Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.	
Column 4	Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")	

Add rows as needed for each research project.

Funder	Description of Research	My Role	End Date
CIHR	Individual patient data meta- analysis antithrombotics in cancer	PI	Mach 2016
			_

Institutional Relationships

П	stitutional Relationships
1.	Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?
	☐ Don't know
	□ No
	⊠ Yes
	If yes, please explain:
	Contract for systematic reviews for these guidelines being negotiated with ASH

5.	Could your institution benefit or be harmed by recommendations of guidelines on this topic?
	☑ Don't know
	\square No
	□ Yes
	If yes, please explain:
	reer Advancement How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?
	N/A
Ac 7.	Vocacy and Policy Positions Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?
	⊠ No
	□ Yes
	If yes, are you involved in formulating or voting for positions?
	□ No
	□ Yes
	If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?
	☐ Don't know or not applicable
	\square No
	□ Yes
	If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

9.	Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
	□ No
	⊠ Yes
	If yes, please explain:
	Diagnosis and treatment of DVT
Ex	spected Interests
10.	Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
	⊠ No
	□ Yes
	If yes, please describe:

Internal Medicine, Public Health, preventive medicine

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	VTE Guideline Coordination Panel Guideline Panel on Diagnosis of VTE Guideline Panel on Prevention of VTE in Medical Hospitalized
	Patients Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer ASH Guidelines on Venous Thromboembolism for Latin America

Approved to participate?	Status	Recusal may be required?	Date reviewed by ASH staff	Notes
Yes	Unconflicted majority	No	5/1/2015; 5/5/2015	
Yes	Unconflicted majority	No	4/26/2018 Alexander	On 4/26/2018, Dr. Schunemann confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

Company	Description	Disclosure Date	ASH Notes

Notes:		

Part A. Material Interests in Companies

Equity				
develops, produces, m treat, monitor, manag	Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.			
⊠ No	⊠ No			
\square Yes, as described b	elow:			
Add rows as needed for	or each equity interest.			
Company Description Date Divested For ASH Internal Use				
•	the past 24 months have y	•	•	
conditions?	rty or product used to diag	nose, treat, monitor, man	age, or alleviate nealth	
⊠ No				
\square Yes, as described b	elow:			
Add rows as needed for	Add rows as needed for each patent or royalty interest.			
Company	Description	Date Divested	For ASH Internal Use	

Personal Income or Other Remuneration

3.	Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?				
	⊠ No				
	☐ Yes, as o	described b	elow:		
	Column 1 Name the company.				
	Column 2	umn 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.			
	Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")			nas not yet ended,	
	Add rows as needed for each activity.				
	To report activities that generate revenues for your institution, see Part B, Question 5.				
С	ompany		Description	End Date	For ASH Internal Use

Do you cur (e.g., in kin drugs, devi	Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?				
⊠ No					
\square Yes, as described below:					
Column 1	Name the company funding or supporting the research.				
Column 2	Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.				
Column 3	Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.				

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	Description of Research	My Role	End Date	For ASH Internal Use

5.	Ay Partner's or Spouse's Interests Currently or in the past 24 months has your partner or spouse had any of the interests described in questions 1-4?				
	⊠ No				
	☐ Yes, as described below:				
	Add rows as needed for each interest.				
Со	mpany	Description	End Date	For ASH Internal Use	

Part B. Interests That Are Not Mainly Financial

You have been invited to participate as a researcher on systematic evidence reviews that will inform clinical practice guidelines by the American Society of Hematology on the following topic:

٧	enous thromboembolism
or	e questions that follow are designed to elicit information about personal beliefs, intellectual positions opinions, institutional relationships, and other interests that are not mainly financial and that may be evant to guidelines on the above topic.
Ре 1.	ersonal Beliefs Do you have strongly held beliefs related to the topic of these guidelines?
	⊠ No □ Yes
	If yes, please explain:
Pr 2.	reviously Published Opinions Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?
	⊠ No
	☐ Yes If yes, what were those views and where were they made?
R€ 3.	Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization? No

	☐ Yes, as	described l	below:		
	Column 1	Name the	entity funding the researc	ch.	
	Column 2 Describe the research project.				
	Column 3	steering c	your role: (a) national or	does not have a principal in	
	Column 4		vhen your involvement end dicate "current" or "ongoil		nvolvement has not yet
	Add rows	as needed f	for each research project.		
Fι	ınder		Description of Research	My Role	End Date
 5. 	No.	nerate reve testifying,	iffected by recommendation of the state of t	r employer by clinical activ	
	□ Yes				
	If yes, plea	se explain:			
6.	Could your	institution	benefit or be harmed by r	ecommendations of guide	lines on this topic?
	☐ Don't kı	now			
	⊠ No				
	☐ Yes				
	If yes, plea	se explain:			

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your contributions to guidelines on this topic generated a strong reaction from peers outside your institution?

No or little influence.

Ac	dvocacy and Policy Positions
8.	Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?
	⊠ No
	☐ Yes. Name of organization(s):
	If yes, are you involved in formulating or voting for positions?
	□ No
	□ Yes
	If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?
	☐ Don't know or not applicable
	□ No
	□ Yes
	If yes, please explain:
Pr	ofessional Specialty
	What is your primary profession? If you are a clinician, what is your clinical specialty or subspecialty?
	Methodologist, not a clinician.
10.	Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?
	⊠ No
	□ Yes
	If yes, please explain:

Expected Interests

11.	Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?
	⊠ No
	□ Yes
	If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publicly available.

Guideline topic:	Systematic reviews on patient values and preferences
	Treatment of VTE (systematic reviews)
	ASH Guidelines on Venous Thromboembolism for Latin America

Approved to participate?	Reviewer name and date	Notes
Yes	10/24/16 Alexander; 10/27/16 Kunkle	No material conflicts of interest

Summarize all current material interests in affected companies described above:

Company	Description	Disclosure Date	ASH Notes

Notes:			